PEGylation—the covalent attachment of polyethylene glycol (PEG) chains to peptides—is a widely used strategy for extending the circulating half-life of therapeutic peptides. By increasing molecular size and shielding the peptide from proteolytic enzymes, PEGylation significantly improves pharmacokinetic properties.
The mechanism of PEGylation involves several factors. The increased molecular size reduces renal clearance, allowing the peptide to remain in circulation longer. The PEG chain also sterically hinders access by proteolytic enzymes, reducing degradation. Additionally, PEGylation can reduce immunogenicity by masking antigenic epitopes on the peptide surface.
PEGylation can be performed at various sites on the peptide, including the N-terminus, lysine side chains, and cysteine residues. Site-specific PEGylation is preferred for therapeutic applications to ensure consistent product quality and predictable pharmacokinetics. The size of the PEG chain can also be varied, with larger PEG chains providing longer half-life extension but potentially reducing activity.
Applications of PEGylation include extending the half-life of peptide hormones (such as GLP-1 analogs), reducing immunogenicity of therapeutic peptides, and improving the solubility of hydrophobic peptides. PEGylation has been successfully applied to numerous approved peptide therapeutics, demonstrating its utility as a modification strategy.
At PeptideHub, we offer site-specific PEGylation services for research and development applications. Our experienced team can design PEGylation strategies that balance half-life extension with maintained activity, providing PEGylated peptides for your specific application. We offer a range of PEG sizes and conjugation chemistries to meet your requirements.